



Toxicological Profile for Chlorinated Dibenzo-*p*-Dioxins

Draft for Public Comment

October 2024



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute-, intermediate-, and chronic-duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S106-5
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA Section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health-related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under Section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
October 2024	Draft for public comment toxicological profile released
November 2012	Addendum to the toxicological profile released
December 1998	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Hana R. Pohl, M.D., Ph.D. (Lead)
Brittany Szafran, D.V.M., Ph.D.
Gaston Casillas, Ph.D.
Fahim Atif, Ph.D.

Lisa Ingerman, Ph.D., D.A.B.T.
Gary L. Diamond, Ph.D.
Heather Carlson-Lynch, M.S., D.A.B.T.
Mario Citra, Ph.D.
Deborah Herber, Ph.D.
Connor McGuire, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. Diane B. Re, Ph.D.; Associate Professor; EHS Department, Columbia University; New York, New York
2. Slawo Lomnicki, Ph.D.; Associate Professor; Department of Environmental Sciences; Louisiana State University; Baton Rouge, Louisiana
3. Stuart Harrad, Ph.D.; Professor of Environmental Chemistry; School of Geography, Earth & Environmental Sciences; University of Birmingham; Birmingham, United Kingdom

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs).....	8
CHAPTER 2. HEALTH EFFECTS.....	15
2.1 INTRODUCTION.....	15
2.2 DEATH	129
2.3 BODY WEIGHT.....	133
2.4 RESPIRATORY	137
2.5 CARDIOVASCULAR.....	140
2.6 GASTROINTESTINAL.....	150
2.7 HEMATOLOGICAL	154
2.8 MUSCULOSKELETAL	157
2.9 HEPATIC.....	159
2.10 RENAL	172
2.11 DERMAL.....	173
2.12 OCULAR	180
2.13 ENDOCRINE.....	181
2.14 IMMUNOLOGICAL	193
2.15 NEUROLOGICAL.....	216
2.16 REPRODUCTIVE	223
2.17 DEVELOPMENTAL.....	242
2.18 OTHER NONCANCER.....	321
2.19 CANCER.....	322
2.20 GENOTOXICITY	338
2.21 MECHANISMS OF TOXICITY	345
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	351
3.1 TOXICOKINETICS.....	351
3.1.1 Absorption.....	351
3.1.2 Distribution	356
3.1.3 Metabolism.....	362
3.1.4 Excretion	366
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	380
3.1.6 Animal-to-Human Extrapolations	396
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	401
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	413
3.3.1 Biomarkers of Exposure.....	414

3.3.2	Biomarkers of Effect	415
3.4	INTERACTIONS WITH OTHER CHEMICALS	415
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		420
4.1	CHEMICAL IDENTITY	420
4.2	PHYSICAL AND CHEMICAL PROPERTIES	424
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		429
5.1	OVERVIEW	429
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	433
5.2.1	Production	433
5.2.2	Import/Export.....	437
5.2.3	Use	437
5.2.4	Disposal.....	437
5.3	RELEASES TO THE ENVIRONMENT.....	441
5.3.1	Air	441
5.3.2	Water.....	446
5.3.3	Soil	446
5.4	ENVIRONMENTAL FATE	448
5.4.1	Transport and Partitioning.....	448
5.4.2	Transformation and Degradation	461
5.5	LEVELS IN THE ENVIRONMENT.....	467
5.5.1	Air	470
5.5.2	Water.....	477
5.5.3	Sediment and Soil	481
5.5.4	Other Media	487
5.6	GENERAL POPULATION EXPOSURE.....	512
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	574
CHAPTER 6. ADEQUACY OF THE DATABASE.....		579
6.1	INFORMATION ON HEALTH EFFECTS.....	579
6.2	IDENTIFICATION OF DATA NEEDS	579
6.3	ONGOING STUDIES.....	595
CHAPTER 7. REGULATIONS AND GUIDELINES		597
CHAPTER 8. REFERENCES		600
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	UPDATE TO THE ATSDR POLICY GUIDELINE FOR DIOXINS AND DIOXIN- LIKE COMPOUNDS IN RESIDENTIAL SOIL	B-1
APPENDIX C.	LITERATURE SEARCH FRAMEWORK FOR CDDs	C-1
APPENDIX D.	FRAMEWORK FOR ATSDR'S SYSTEMIC REVIEW OF HEALTH EFFECTS DATA FOR CDDs.....	D-1
APPENDIX E.	USER'S GUIDE	E-1
APPENDIX F.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	F-1
APPENDIX G.	GLOSSARY.....	G-1
APPENDIX H.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	H-1

LIST OF FIGURES

1-1. Basic Chemical Structure of Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs), Chlorodibenzofurans (CDFs), and Polychlorinated Biphenyls (PCBs)	3
1-2. Health Effects Found in Animals Following Oral Exposure to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	5
1-3. Health Effects Found in Animals Following Oral Exposure to Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs).....	6
1-4. Summary of Sensitive Targets of 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) – Oral	8
1-5. Summary of Sensitive Targets of 2,7-Dichlorodibenzo- <i>p</i> -Dioxin (2,7-DCDD) – Oral	9
1-6. Summary of Sensitive Targets of 2,3,7-Trichlorodibenzo- <i>p</i> -Dioxin (2,3,7-TrCDD) – Oral.....	9
1-7. Summary of Sensitive Targets of 1,2,3,7,8-Pentachlorodibenzo- <i>p</i> -Dioxin (1,2,3,7,8-PeCDD) – Oral	10
1-8. Summary of Sensitive Targets of 1,2,4,7,8-Pentachlorodibenzo- <i>p</i> -Dioxin (1,2,4,7,8-PeCDD) – Oral	10
1-9. Summary of Sensitive Targets of 1,2,3,4,7,8-Hexachlorodibenzo- <i>p</i> -Dioxin (1,2,3,4,7,8-HxCDD) – Oral.....	11
1-10. Summary of Sensitive Targets of 1,2,3,6,7,8-Hexachlorodibenzo- <i>p</i> -Dioxin (1,2,3,6,7,8-HxCDD) – Oral.....	11
1-11. Summary of Sensitive Targets of 1,2,3,4,6,7,8-Heptachlorodibenzo- <i>p</i> -Dioxin (HpCDD) – Oral.....	12
1-12. Summary of Sensitive Targets of Octachlorodibenzo- <i>p</i> -Dioxin (OCDD) – Oral	12
2-1. Overview of the Number of Studies Examining Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) Human Health Effects	26
2-2. Overview of the Number of Animal Studies Examining 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) Health Effects	27
2-3. Overview of the Number of Animal Studies Examining Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) Health Effects.....	28
2-4. Levels of Significant Exposure to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) – Oral	79
2-5. Levels of Significant Exposure to Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) – Oral	114
3-1. A Generalized Scheme of Pathways for the Biotransformation of CDDs Based on Information from <i>In Vivo</i> Mammalian Studies.....	365
5-1. Number of NPL Sites with Chlorinated Dibenzo- <i>p</i> -Dioxin (CDD) Contamination.....	429

6-1. Summary of Existing Human Health Effects Studies on Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) by Route and Endpoint.....	580
6-2. Summary of Existing Animal Health Effects Studies on 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) by Route and Endpoint	581
6-3. Summary of Existing Health Effects Animal Studies on Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) by Route and Endpoint.....	582

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (2,3,7,8-TCDD).....	13
1-2. Minimal Risk Levels (MRLs) for Other CDD Congeners	14
2-1. Summary of World Health Organization (WHO) 1998, 2005, and 2022 Toxic Equivalency Factors (TEFs).....	18
2-2. Levels of Significant Exposure to 2,3,7,8-Tetrachloroibenzo- <i>p</i> -Dioxin – Oral	29
2-3. Levels of Significant Exposure to Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) – Oral	103
2-4. Levels of Significant Exposure to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) – Dermal	125
2-5. Levels of Significant Exposure to Other Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) – Dermal	128
2-6. LD ₅₀ Values in Laboratory Animals Following a Single Oral Dose of 2,3,7,8-TCDD.....	130
2-7. LD ₅₀ Values in Laboratory Animals Following a Single Oral Dose of Other CDD Congeners	132
2-8. Alterations in Body Weight in Animals Orally Exposed to Other CDD Congeners.....	137
2-9. Cardiovascular Effects in Humans Exposed to TCDD/CDDs.....	142
2-10. Gastrointestinal Effects in Humans Exposed to TCDD/CDDs.....	151
2-11. Hepatic Effects in Humans Exposed to TCDD/CDDs	161
2-12. Hepatic Clinical Chemistry in Rats and Mice Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD).....	166
2-13. Histopathological Alterations in the Liver of Experimental Animals Resulting From Oral Exposure to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD).....	168
2-14. Endocrine Effects in Humans Exposed to TCDD/CDDs	182
2-15. Results of Studies Evaluating Thyroid Outcomes in Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD).....	190
2-16. Immunological Effects in Humans Exposed to TCDD/CDDs	195
2-17. Results of Studies Evaluating Immunosuppression in Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD).....	204
2-18. Numbers of Aryl Hydrocarbon Receptor Responsive Elements (AhREs) in Genes Regulating T Helper Cell Differentiation.....	215
2-19. Neurological Effects in Humans Exposed to TCDD/CDDs.....	217
2-20. Reproductive Effects in Humans Exposed to TCDD/CDDs	225

2-21. Effects on Reproductive Hormone Levels in Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	235
2-22. Reproductive Effects in Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (2,3,7,8-TCDD)	237
2-23. Developmental Effects in Humans Exposed to TCDD/CDDs	244
2-24. Structural Anomalies in Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	290
2-25. Systemic Effects Observed in the Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	292
2-26. Immunological Effects in the Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	297
2-27. Impaired Development of Reproductive System in Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	305
2-28. Functional Alterations in the Reproductive System of Male Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	309
2-29. Functional Alterations in the Reproductive System of Female Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	311
2-30. Alterations in Reproductive Hormones in the Male Offspring of Laboratory Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	314
2-31. Cancer Effects in Humans Exposed to TCDD/CDDs	323
2-32. Occupational Cohort Studies Examining the Carcinogenicity of Chlorinated Dibenz- <i>p</i> -Dioxins (CDDs)	331
2-33. Carcinogenic Effects in Animals Orally Exposed to 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	333
2-34. Genotoxic Effects in Humans Exposed to 2,3,7,8-TCDD/CDDs	339
2-35. Genotoxicity of 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) <i>In Vivo</i>	340
2-36. Genotoxicity of 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) <i>In Vitro</i>	343
2-37. Genes with Functional Aryl Hydrocarbon Response (AhR) Responsive Elements (AhREs).....	346
2-38. Examples of AhR:ARNT Canonical Pathway Effects	347
2-39. Examples of Non-canonical AhR Signaling	347
3-1. Mean Levels of CDDs in Human Milk (ng/kg Milk Fat).....	372
3-2. Comparison of Health Effects Among Species Exposed to CDDs.....	397

3-3. Comparison of LOAELs Among Animal Species Following a Single Oral Dose of 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD)	397
3-4. AhR-TCDD Equilibrium Dissociation Constants (K_d) in various Laboratory Species and Human Tissues	400
4-1. Chemical Identity of CDDs	421
4-2. Physical and Chemical Properties of CDDs	425
5-1. Facilities that Produce, Process, or Use Dioxin and Dioxin-like Compounds	435
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Dioxin and Dioxin-like Compounds	442
5-3. Rain Scavenging Ratios (RS) and Percent Washout Due to Particulates (%W) for CDDs and CDFs in Ambient Air in Two Midwest Cities.....	450
5-4. Bioconcentration Factors (BCFs) for Aquatic Organisms.....	451
5-5. Estimated Upper Trophic Bioaccumulation Factors (BAFs) for MCDD Through OCDD	453
5-6. Estimated Log K_{oc} for MCDD through OCDD	458
5-7. Lowest Limit of Detection Based on Standards	468
5-8. Summary of Environmental Levels of Chlorinated Dibenzo- <i>p</i> -Dioxins	468
5-9. Chlorinated Dibenzo- <i>p</i> -Dioxin Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	469
5-10. Congener-specific Monitoring Data from the National Dioxin Air Monitoring Network 1998–2004	470
5-11. Concentrations of CDDs in Ambient Indoor and Outdoor Air in North America and Oceans	472
5-12. Porewater Concentrations of CDDs (pg/L) at Four Locations of the Lower Passaic River Obtained During Four Sampling Periods	477
5-13. CDD Levels in a Soil Sample Taken from a Sampling Location in East Palestine, Ohio, March 12, 2023.....	481
5-14. 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) Levels Measured in Soil Samples Collected in 1984 from Industrialized Areas of U.S. Cities	483
5-15. Detections of CDD Congeners in Food Items from the 2004 FDA Market Basket Survey	488
5-16. Dioxins, Dibenzofurans, and Dioxin Toxic Equivalencies (TEQs) in U.S. Foods (ppt or pg/g, Wet Weight)	498
5-17. Overall National Averages of the Concentrations (ppt or pg/g) of CDDs in Fat of Meat and Milk on a Lipid Basis	499

5-18. Levels of CDDs in Fish and Other Aquatic Organisms.....	502
5-19. Concentrations of CDDs (pg/g Lipid [ppt]) in Benthic Species Collected from the Lower Passaic River	504
5-20. Summary of CDDs Detected in Fish Tissue as Part of the EPA National Study of Chemical Residues in Fish.....	506
5-21. Mean Dioxin Exposure from Beef, Based on Beef Consumption.....	513
5-22. Estimated Average Daily Intake of 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (2,3,7,8-TCDD) by the General U.S. Population	514
5-23. Estimated Daily Background Exposure to Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs) and Chlorinated Dibenzofurans in the General U.S. Population.....	514
5-24. Dietary CDD/CDF Exposure Estimate (pg WHO-TEQ/kg Body Weight/Month) by Food Category from TDS Foods Collected in 2001–2004	515
5-25. Estimated Intake of CDDs and CDFs from Meat, Poultry, and Fish.....	516
5-26. Estimated Average Daily Intake of TEQs Associated with Exposure to a Typical State-of-the-Art Municipal Waste Incinerator.....	518
5-27. Chlorinated Dioxins and Dibenzofurans in Adipose Tissue of the General Population.....	520
5-28. Serum 1,2,3,4,6,7,8-HpCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	522
5-29. Serum 1,2,3,4,7,8-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	524
5-30. Serum 1,2,3,6,7,8-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	526
5-31. Serum 1,2,3,7,8,9-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	528
5-32. Serum 1,2,3,4,6,7,8,9-OCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	530
5-33. Serum 1,2,3,7,8-PeCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	532
5-34. Serum 2,3,7,8-TCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	534
5-35. Serum 1,2,3,4,6,7,8-HpCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	536
5-36. Serum 1,2,3,4,7,8-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	541

5-37. Serum 1,2,3,6,7,8-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	546
5-38. Serum 1,2,3,7,8,9-HxCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	551
5-39. Serum 1,2,3,4,6,7,8,9-OCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	556
5-40. Serum 1,2,3,7,8-PeCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	561
5-41. Serum 2,3,7,8-TCDD (Lipid Adjusted) Concentrations (pg/g Lipid) for the U.S. Population.....	566
5-42. Blood TEQ Levels for Dioxin-Like Compounds (CDDs, CDFs, and select PCBs) Levels (pg/g Lipid) at 90 th and 95 th Percentiles by Age Group in NHANES 2001–2002 and 2003–2004 Survey Years	571
5-43. Serum CDD/CDF Concentrations for Mean and Selected Percentiles for the NHANES 1999–2000, 2001–2002, and 2003–2004 Survey Years.....	571
5-44. Mean and Range (ppt) of Serum CDD (Lipid Adjusted).....	577
6-1. Ongoing Studies on Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs)	596
7-1. Regulations and Guidelines Applicable to Chlorinated Dibenzo- <i>p</i> -Dioxins (CDDs)	597